Effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active Crohn's disease: Week 12 results from the Phase 2 GALAXI 1 study

被引：0

作者：

Leong, R. W-L ^{[1
,2
,3
]}

D'Haens, G. ^{[4
]}

Rubin, D. T. ^{[5
]}

Panes, J. ^{[7
]}

Gonzalez, S. ^{[6
]}

Chan, D. ^{[6
]}

Johanns, J. ^{[6
]}

Frustaci, M. E. ^{[6
]}

Yang, Z. ^{[6
]}

Adedokun, O. J. ^{[6
]}

Cunningham, M. ^{[6
]}

Ghanem, L. ^{[6
]}

Reinisch, W. ^{[8
]}

Hisamatsu, T. ^{[9
]}

Feagan, B. G. ^{[10
]}

机构：

[1] Univ Sydney, Sydney, NSW, Australia

[2] UNSW, Sydney, NSW, Australia

[3] Macquarie Univ, Sydney, NSW, Australia

[4] Amsterdam UMC, Amsterdam, Netherlands

[5] Univ Chicago, Med Inflammatory Bowel Dis Ctr, Chicago, IL 60637 USA

[6] Janssen Res & Dev, Philadelphia, PA USA

[7] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

[8] Med Univ Vienna, Vienna, Austria

[9] Kyorin Univ, Tokyo, Japan

[10] Western Univ, Robarts Clin Trials, London, ON, Canada

来源：

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：169 / 170

页数：2